Oxford University, along with AstraZeneca plc from Great Britain (AZN) – Get report It released promising data from an early-stage trial of a key coronavirus vaccine study in London on Monday that could lead to wider use by the end of the year.
The details, published in the British medical journal The Lancet, showed what the two groups described as humoral and cellular immune responses in human trials, with an acceptable safety profile. The study also showed “potent” cellular and humoral immunogenicity in all 1,077 participants in the Phase 1 / Phase II study.
“Provisional Phase I / II data for our coronavirus vaccine show that the vaccine did not cause any unexpected reactions and had a similar safety profile to previous vaccines of this type,” said Andrew Pollard, chief investigator of the Vaccine Trial. from Oxford to Oxford. University and trial co-author. “The immune responses observed after vaccination are in line with what we hope will be associated with protection against the SARS-CoV-2 virus, although we must continue our rigorous clinical trial program to confirm this. ”
“We saw the strongest immune response in participants who received two doses of the vaccine, indicating that this could be a good strategy for vaccination,” he added.
AstraZeneca shares hit a record high in London trading on Monday after rising 5.9% on the session. Meanwhile, the group’s US-listed shares fell 3.6% in early trading on the New York Stock Exchange to change hands at $ 59.00 each.
Rival shares of Pfizer also moved Monday, rising 2.1% on the New York Stock Exchange to $ 37.00 a share, after the drug maker reached an agreement to sell 30 million doses of its experimental vaccine against the coronavirus to the British government.
Pfizer, which is working on two candidates for its BNT162 mRNA-based vaccine program in collaboration with BioNTech Inc. BNTX of Germany, will supply 30 million doses, at an undisclosed price, once it is approved by regulators. However, UK Prime Minister Boris Johnson said Monday that it would be “overkill” to suggest that a vaccine would be available for “this year or next … We are not there yet.”
Modern Inc. (MRNA) – Get report Shares, meanwhile, fell 15.3% before being suspended from trading due to extreme volatility on the Nasdaq. Moderna said last week that its proposal for a coronavirus vaccine induced antibody reactions in the 45 participating patients, without serious side effects, after two injections spanning a four-week period.
The results open the door to a larger study of some 30,000 patients, scheduled for July 27.
.
